Reuters logo
BRIEF-Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis
February 8, 2017 / 1:10 PM / 10 months ago

BRIEF-Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis

Feb 8 (Reuters) - Veracyte Inc

* Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis through agreement with quest diagnostics

* Says quest diagnostics is expected to begin offering test to its customers nationally in Q2 of 2017

* Says financial and other terms of agreement were not disclosed.

* Physician clients of quest diagnostics will be able to order test on behalf of patients, refer patient specimens to co for genomic testing Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below